The DOI matches its Crossref record; 280 of the 280 references it cites were found in a registry or an index.
Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target
Open accessAbstract
Apolipoprotein (apo) B, the critical structural protein of the atherogenic lipoproteins, has two major isoforms: apoB48 and apoB100. ApoB48 is found in chylomicrons and chylomicron remnants with one apoB48 molecule per chylomicron particle. Similarly, a single apoB100 molecule is contained per particle of very-low-density lipoprotein (VLDL), intermediate density lipoprotein, LDL and lipoprotein(a). This unique one apoB per particle ratio makes plasma apoB concentration a direct measure of the number of circulating atherogenic lipoproteins. ApoB levels indicate the atherogenic particle concentration independent of the particle cholesterol content, which is variable. While LDL, the major cholesterol-carrying serum lipoprotein, is the primary therapeutic target for management and prevention of atherosclerotic cardiovascular disease, there is strong evidence that apoB is a more accurate indicator of cardiovascular risk than either total cholesterol or LDL cholesterol. This review examines multiple aspects of apoB structure and function, with a focus on the controversy over use of apoB as a therapeutic target in clinical practice. Ongoing coronary artery disease residual risk, despite lipid-lowering treatment, has left patients and clinicians with unsatisfactory options for monitoring cardiovascular health. At the present time, the substitution of apoB for LDL-C in cardiovascular disease prevention guidelines has been deemed unjustified, but discussions continue.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036 · cited 1×
“According to the American Heart Association (AHA), one in three people will be affected by some form of CVD during their lifetime [3].”
BackgroundMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study
D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.699579 · Cited by 7,491
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Heart Disease and Stroke Statistics—2010 Update: A Report From the American Heart Association
WRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192667 · Cited by 5,700
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
(2019) · doi:10.1161/cir.0000000000000677 · Cited by 4,501
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437741.48606.98 · Cited by 3,697
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634 · cited 1×
“These PCSK9 inhibitors are used to treat primary hyperlipidemia and have been found to reduce myocardial infarction and stroke in persons with established CVD [227,228].”
BackgroundEffects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Silverman, M. G., Ference, B. A., Im, K., Wiviott, S. D., Giugliano, R. P., Grundy, S. M., Braunwald, E., & Sabatine, M. S. (2016) · JAMA · doi:10.1001/jama.2016.13985 · Cited by 1,483 · cited 1×
“However, CVD risk reduction achieved via lipid-lowering therapy in most clinical studies does not exceed 30% [87,98].”
BackgroundWRITING GROUP MEMBERS, Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.192666 · Cited by 1,359
Walldius, G., Jungner, I., Holme, I., Aastveit, A. H., Kolar, W., & Steiner, E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07098-2 · Cited by 1,229
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.009 · Cited by 1,193
Demographic and epidemiologic drivers of global cardiovascular mortality
Roth, G. A., Forouzanfar, M. H., Moran, A. E., Barber, R., Nguyen, G., Feigin, V. L., Naghavi, M., Mensah, G. A., & Murray, C. J. L. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406656 · Cited by 1,188
Effects of anacetrapib in patients with atherosclerotic vascular disease
The HPS3/TIMI55–REVEAL Collaborative Group (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706444 · Cited by 1,047
A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine
Powell, L. M., Wallis, S. C., Pease, R. J., Edwards, Y. H., Knott, T. J., & Scott, J. (1987) · Cell · doi:10.1016/0092-8674(87)90510-1 · Cited by 1,038
Subendothelial retention of atherogenic lipoproteins in early atherosclerosis
Skålén, K., Gustafsson, M., Rydberg, E. K., Hultén, L. M., Wiklund, O., Innerarity, T. L., & Borén, J. (2002) · Nature · doi:10.1038/nature00804 · Cited by 1,019
Metabolic origins and clinical significance of LDL heterogeneity
Berneis, K. K., & Krauss, R. M. (2002) · Journal of Lipid Research · doi:10.1194/jlr.r200004-jlr200 · Cited by 896
Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis
Barter, P. J., Brewer, H. B., Chapman, M. J., Hennekens, C. H., Rader, D. J., & Tall, A. R. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000054658.91146.64 · Cited by 870
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Ray, K. K., Bays, H. E., Catapano, A. L., Lalwani, N. D., Bloedon, L. T., Sterling, L. R., Robinson, P. L., & Ballantyne, C. M. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1803917 · Cited by 807
Evacetrapib and cardiovascular outcomes in high-risk vascular disease
Lincoff, A. M., Nicholls, S. J., Riesmeyer, J. S., Barter, P. J., Brewer, H. B., Fox, K. A. A., Gibson, C. M., Granger, C., Menon, V., Montalescot, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609581 · Cited by 801
Ference, B. A., Kastelein, J. J. P., Ray, K. K., Ginsberg, H. N., Chapman, M. J., Packard, C. J., Laufs, U., Oliver-Williams, C., Wood, A. M., Butterworth, A. S., et al. (2019) · JAMA · doi:10.1001/jama.2018.20045 · Cited by 703 · cited 1×
“in 2019 [212] shed light on the importance of apoB particle number in determining CHD risk.”
BackgroundMcClelland, R. L., Jorgensen, N. W., Budoff, M., Blaha, M. J., Post, W. S., Kronmal, R. A., Bild, D. E., Shea, S., Liu, K., Watson, K. E., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.08.035 · Cited by 681
Sniderman, A. D., Williams, K., Contois, J. H., Monroe, H. M., McQueen, M. J., de Graaf, J., & Furberg, C. D. (2011) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.959247 · Cited by 659
The metabolism of low density lipoprotein in familial type II hyperlipoproteinemia
Langer, T., Strober, W., & Levy, R. I. (1972) · Journal of Clinical Investigation · doi:10.1172/jci106949 · Cited by 629
WALLDIUS, G., & JUNGNER, I. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01643.x · Cited by 583
Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events
Boekholdt, S. M., Hovingh, G. K., Mora, S., Arsenault, B. J., Amarenco, P., Pedersen, T. R., LaRosa, J. C., Waters, D. D., DeMicco, D. A., Simes, R. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.615 · Cited by 581
Recent trends in cardiovascular mortality in the United States and public health goals.
Sidney, S., Quesenberry, C. P., Jaffe, M. G., Sorel, M., Nguyen-Huynh, M. N., Kushi, L. H., Go, A. S., & Rana, J. S. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.1326 · Cited by 569
Walldius, G., Jungner, I., Holme, I., Aastveit, A. H., Kolar, W., & Steiner, E. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00666-9 · Cited by 534
Structure of apolipoprotein B-100 in low density lipoproteins
Segrest, J. P., Jones, M. K., De Loof, H., & Dashti, N. (2001) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30267-4 · Cited by 522
Inflammation and its Resolution as Determinants of Acute Coronary Syndromes
Libby, P., Tabas, I., Fredman, G., & Fisher, E. A. (2014) · Circulation Research · doi:10.1161/circresaha.114.302699 · Cited by 521
Pischon, T., Girman, C. J., Sacks, F. M., Rifai, N., Stampfer, M. J., & Rimm, E. B. (2005) · Circulation · doi:10.1161/circulationaha.104.532499 · Cited by 514
Hepatic uptake of chylomicron remnants
Cooper, A. D. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34932-4 · Cited by 499
Sacks, F. M., Alaupovic, P., Moye, L. A., Cole, T. G., Sussex, B., Stampfer, M. J., Pfeffer, M. A., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.102.16.1886 · Cited by 490
Regulation of the activity of the low density lipoprotein receptor in human fibroblasts
Brown, M. S., & Goldstein, J. L. (1975) · Cell · doi:10.1016/0092-8674(75)90182-8 · Cited by 482
BARTER, P. J., BALLANTYNE, C. M., CARMENA, R., CABEZAS, M. C., CHAPMAN, M. J., COUTURE, P., DE GRAAF, J., DURRINGTON, P. N., FAERGEMAN, O., FROHLICH, J., et al. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01616.x · Cited by 464
Fruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.002 · Cited by 463
Fisher, E. A., & Ginsberg, H. N. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.r100068200 · Cited by 460
Small Dense Low‐Density Lipoprotein as Biomarker for Atherosclerotic Diseases
Ivanova, E. A., Myasoedova, V. A., Melnichenko, A. A., Grechko, A. V., & Orekhov, A. N. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/1273042 · Cited by 457
Sampson, U. K., Fazio, S., & Linton, M. F. (2012) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0219-7 · Cited by 439
Hevonoja, T., Pentikäinen, M. O., Hyvönen, M. T., Kovanen, P. T., & Ala-Korpela, M. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(00)00123-2 · Cited by 436
Bachorik, P. S., & Ross, J. W. (1995) · Clinical Chemistry · doi:10.1093/clinchem/41.10.1414 · Cited by 412
Jagannathan, R., Patel, S. A., Ali, M. K., & Narayan, K. M. V. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1161-2 · Cited by 369
Dixon, J., & Ginsberg, H. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)40744-8 · Cited by 368
Foam cell formation: A new target for fighting atherosclerosis and cardiovascular disease
Maguire, E. M., Pearce, S. W. A., & Xiao, Q. (2019) · Vascular Pharmacology · doi:10.1016/j.vph.2018.08.002 · Cited by 366
Protein disulfide isomerase is a component of the microsomal triglyceride transfer protein complex.
Wetterau, J. R., Combs, K. A., Spinner, S. N., & Joiner, B. J. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38742-3 · Cited by 365
Apolipoprotein B: Structural and Metabolic Heterogeneity
Kane, J. P. (1983) · Annual Review of Physiology · doi:10.1146/annurev.ph.45.030183.003225 · Cited by 349
OLOFSSON, S. ‐., & BORÈN, J. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01556.x · Cited by 330
Contois, J. H., McConnell, J. P., Sethi, A. A., Csako, G., Devaraj, S., Hoefner, D. M., & Warnick, G. R. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.118356 · Cited by 326
Borén, J., Olin, K., Lee, I., Chait, A., Wight, T. N., & Innerarity, T. L. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2265 · Cited by 320
Dunbar, S. B., Khavjou, O. A., Bakas, T., Hunt, G., Kirch, R. A., Leib, A. R., Morrison, R. S., Poehler, D. C., Roger, V. L., & Whitsel, L. P. (2018) · Circulation · doi:10.1161/cir.0000000000000570 · Cited by 319
Apolipoprotein B: mRNA Editing, Lipoprotein Assembly, and Presecretory Degradation
Davidson, N. O., & Shelness, G. S. (2000) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.20.1.169 · Cited by 311
Ference, B. A., Kastelein, J. J. P., Ginsberg, H. N., Chapman, M. J., Nicholls, S. J., Ray, K. K., Packard, C. J., Laufs, U., Brook, R. D., Oliver-Williams, C., et al. (2017) · JAMA · doi:10.1001/jama.2017.11467 · Cited by 304
Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review
De Vera, M. A., Bhole, V., Burns, L. C., & Lacaille, D. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12339 · Cited by 289
Fisher, E. A., Zhou, M., Mitchell, D. M., Wu, X., Omura, S., Wang, H., Goldberg, A. L., & Ginsberg, H. N. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.33.20427 · Cited by 286
Caloric Sweetener Consumption and Dyslipidemia Among US Adults
Welsh, J. A. (2010) · JAMA · doi:10.1001/jama.2010.449 · Cited by 276
LDL cholesterol: controversies and future therapeutic directions
Ridker, P. M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61009-6 · Cited by 274
Davidson, M. H., Maki, K. C., Pearson, T. A., Pasternak, R. C., Deedwania, P. C., McKenney, J. M., Fonarow, G. C., Maron, D. J., Ansell, B. J., Clark, L. T., et al. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.04.019 · Cited by 270
Cheng, K., Wu, T.-J., Wu, K. K., Sturino, C., Metters, K., Gottesdiener, K., Wright, S. D., Wang, Z., O’Neill, G., Lai, E., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601574103 · Cited by 268
Intracellular Trafficking and Secretion of VLDL
Tiwari, S., & Siddiqi, S. A. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.241471 · Cited by 256
Öörni, K., Pentikäinen, M. O., Ala-Korpela, M., & Kovanen, P. T. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)31964-7 · Cited by 252
Nordestgaard, B. G., Langlois, M. R., Langsted, A., Chapman, M. J., Aakre, K. M., Baum, H., Borén, J., Bruckert, E., Catapano, A., Cobbaert, C., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.12.005 · Cited by 246 · cited 1×
“ApoB has been proposed as a better predictor of MCVE because a single molecule is found in every atherogenic particle and LDL-C levels alone can miss elevated particle numbers [271].”
BackgroundLipid disorders and mutations in the APOB gene
Whitfield, A. J., Barrett, P. H. R., van Bockxmeer, F. M., & Burnett, J. R. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.038026 · Cited by 243
Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions
Packard, C. J., Demant, T., Stewart, J. P., Bedford, D., Caslake, M. J., Schwertfeger, G., Bedynek, A., Shepherd, J., & Seidel, D. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32065-4 · Cited by 239
Boren, J., Lee, I., Zhu, W., Arnold, K., Taylor, S., & Innerarity, T. L. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1847 · Cited by 234
Apolipoprotein B, the major protein component of triglyceride-rich and low density lipoproteins.
Chan, L. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35646-1 · Cited by 231
Knopp, R. H., Ginsberg, J., Albers, J. J., Hoff, C., Ogilvie, J. T., Warnick, G. R., Burrows, E., Retzlaff, B., & Poole, M. (1985) · Metabolism · doi:10.1016/0026-0495(85)90092-7 · Cited by 231
Atherogenicity of Triglyceride-Rich Lipoproteins
Krauss, R. M. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00032-0 · Cited by 227
Zheng, C., Khoo, C., Furtado, J., & Sacks, F. M. (2010) · Circulation · doi:10.1161/circulationaha.109.875807 · Cited by 223
Nicholls, S. J., Tuzcu, E. M., Brennan, D. M., Tardif, J.-C., & Nissen, S. E. (2008) · Circulation · doi:10.1161/circulationaha.108.790733 · Cited by 213
Langlois, M. R., Nordestgaard, B. G., Langsted, A., Chapman, M. J., Aakre, K. M., Baum, H., Borén, J., Bruckert, E., Catapano, A., Cobbaert, C., et al. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-1253 · Cited by 211
Klingenberg, R., Lebens, M., Hermansson, A., Fredrikson, G. N., Strodthoff, D., Rudling, M., Ketelhuth, D. F. J., Gerdes, N., Holmgren, J., Nilsson, J., et al. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.109.202671 · Cited by 201
Ginsberg, H. N. (1998) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70023-2 · Cited by 194
Carr, S. S., Hooper, A. J., Sullivan, D. R., & Burnett, J. R. (2019) · Pathology · doi:10.1016/j.pathol.2018.11.006 · Cited by 193
Niacin and cholesterol: role in cardiovascular disease (review)
Ganji, S. H., Kamanna, V. S., & Kashyap, M. L. (2003) · The Journal of Nutritional Biochemistry · doi:10.1016/s0955-2863(02)00284-x · Cited by 189
The Triple Threat to Nascent Apolipoprotein B
Fisher, E. A., Pan, M., Chen, X., Wu, X., Wang, H., Jamil, H., Sparks, J. D., & Williams, K. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008885200 · Cited by 189
Wilkins, J. T., Li, R. C., Sniderman, A., Chan, C., & Lloyd-Jones, D. M. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.055 · Cited by 181
Morita, S. (2015) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b15-00716 · Cited by 180
Segrest, J. P., Jones, M. K., Mishra, V. K., Anantharamaiah, G. M., & Garber, D. W. (1994) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.14.10.1674 · Cited by 176
Cardiovascular disease and modifiable cardiometabolic risk factors
Cannon, C. P. (2007) · Clinical Cornerstone · doi:10.1016/s1098-3597(07)80025-1 · Cited by 175
Sahebkar, A., & Watts, G. F. (2013) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-013-6479-4 · Cited by 175
MDGs: chronic diseases are not on the agenda
Fuster, V., & Voûte, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67610-6 · Cited by 171
Sturino, C. F., O'Neill, G., Lachance, N., Boyd, M., Berthelette, C., Labelle, M., Li, L., Roy, B., Scheigetz, J., Tsou, N., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0603668 · Cited by 171
Sierra-Johnson, J., Fisher, R. M., Romero-Corral, A., Somers, V. K., Lopez-Jimenez, F., Ohrvik, J., Walldius, G., Hellenius, M.-L., & Hamsten, A. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn347 · Cited by 170
Tsimikas, S., Clopton, P., Brilakis, E. S., Marcovina, S. M., Khera, A., Miller, E. R., de Lemos, J. A., & Witztum, J. L. (2009) · Circulation · doi:10.1161/circulationaha.108.836940 · Cited by 169
Measurement of low-density-lipoprotein cholesterol in serum: a status report
Rifai, N., Warnick, G. R., McNamara, J. R., Belcher, J. D., Grinstead, G. F., & Frantz, I. D. (1992) · Clinical Chemistry · doi:10.1093/clinchem/38.1.150 · Cited by 169
Thirty-One Novel Biomarkers as Predictors for Clinically Incident Diabetes
Salomaa, V., Havulinna, A., Saarela, O., Zeller, T., Jousilahti, P., Jula, A., Muenzel, T., Aromaa, A., Evans, A., Kuulasmaa, K., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010100 · Cited by 169
Sequí‐Domínguez, I., Cavero‐Redondo, I., Álvarez‐Bueno, C., Pozuelo‐Carrascosa, D. P., de Arenas‐Arroyo, S. N., & Martínez‐Vizcaíno, V. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072080 · Cited by 169
Postprandial lipoprotein metabolism: VLDL vs chylomicrons
Nakajima, K., Nakano, T., Tokita, Y., Nagamine, T., Inazu, A., Kobayashi, J., Mabuchi, H., Stanhope, K. L., Havel, P. J., Okazaki, M., et al. (2011) · Clinica Chimica Acta · doi:10.1016/j.cca.2011.04.018 · Cited by 168
Paolini, J. F., Mitchel, Y. B., Reyes, R., Kher, U., Lai, E., Watson, D. J., Norquist, J. M., Meehan, A. G., Bays, H. E., Davidson, M., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.10.023 · Cited by 163
Benn, M., Nordestgaard, B. G., Jensen, G. B., & Tybjærg‐Hansen, A. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000255580.73689.8e · Cited by 163
Lipid transfer proteins in the assembly of apoB-containing lipoproteins
Sirwi, A., & Hussain, M. M. (2018) · Journal of Lipid Research · doi:10.1194/jlr.r083451 · Cited by 160
The composition and metabolism of large and small LDL
Diffenderfer, M. R., & Schaefer, E. J. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000067 · Cited by 159
Jungner, I., Marcovina, S. M., Walldius, G., Holme, I., Kolar, W., & Steiner, E. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.8.1641 · Cited by 158
Bachorik, P. S., Lovejoy, K. L., Carroll, M. D., & Johnson, C. L. (1997) · Clinical Chemistry · doi:10.1093/clinchem/43.12.2364 · Cited by 155
Sundaram, M., & Yao, Z. (2010) · Nutrition & Metabolism · doi:10.1186/1743-7075-7-35 · Cited by 154
The Friedewald Formula Underestimates LDL Cholesterol at low Concentrations
Scharnagl, H., Nauck, M. A., Wieland, H., & März, W. (2001) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2001.068 · Cited by 141
Kulinski, A., Rustaeus, S., & Vance, J. E. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202015200 · Cited by 140
Regulated Co-translational Ubiquitination of Apolipoprotein B100
Zhou, M., Fisher, E. A., & Ginsberg, H. N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.38.24649 · Cited by 139
Determining When to Add Nonstatin Therapy
Robinson, J. G., Huijgen, R., Ray, K. K., Persons, J. E., Kastelein, J. J. P., & Pencina, M. J. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.09.928 · Cited by 137
Fogacci, F., Ferri, N., Toth, P. P., Ruscica, M., Corsini, A., & Cicero, A. F. G. (2019) · Drugs · doi:10.1007/s40265-019-01114-z · Cited by 132
The physiological and molecular regulation of lipoprotein assembly and secretion
Blasiole, D. A., Davis, R. A., & Attie, A. (2007) · Molecular BioSystems · doi:10.1039/b700706j · Cited by 132
Comparative Effects of Lovastatin and Niacin in Primary Hypercholesterolemia: A Prospective Trial
Illingworth, D. R., Stein, E. A., Mitchel, Y. B., Dujovne, C. A., Frost, P. H., Knopp, R. H., Tun, P., Zupkis, R. V., & Greguski, R. A. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.154.14.1586 · Cited by 132
Williams, K., Sniderman, A. D., Sattar, N. A., D’Agostino, R., Wagenknecht, L. E., & Haffner, S. M. (2003) · Circulation · doi:10.1161/01.cir.0000097113.11419.9e · Cited by 131
Biosynthesis of Apolipoprotein B48-containing Lipoproteins
Innerarity, T. L., Borén, J., Yamanaka, S., & Olofsson, S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.5.2353 · Cited by 130
Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition
Rosenblit, P. D. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1178-6 · Cited by 127
Maccubbin, D., Bays, H. E., OLSSON, A. G., Elinoff, V., Elis, A., Mitchel, Y., Sirah, W., Betteridge, A., Reyes, R., Yu, Q., et al. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01938.x · Cited by 120
Mikhailidis, D. P., Elisaf, M., Rizzo, M., Berneis, K. K., Griffin, B. A., Zambon, A., Athyros, V. G., Graaf, J. D., März, W., Parhofer, K. G., et al. (2011) · Current Vascular Pharmacology · doi:10.2174/157016111796642698 · Cited by 116
Familial Hypercholesterolemia: Global Burden and Approaches
Tokgözoğlu, L. S., & Kayıkçıoğlu, M. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01565-5 · Cited by 115
Onat, A., Can, G., Hergenç, G., Yazıcı, M., Karabulut, A., & Albayrak, S. (2007) · International Journal of Obesity · doi:10.1038/sj.ijo.0803552 · Cited by 112
The New Pooled Cohort Equations Risk Calculator
Preiss, D., & Kristensen, S. L. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.02.001 · Cited by 110
VLDL triglyceride kinetics in lean, overweight, and obese men and women
Mittendorfer, B., Yoshino, M., Patterson, B. W., & Klein, S. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1500 · Cited by 108
Law, S. W. T., Lackner, K. J., Hospattankar, A. V., Anchors, J. M., Sakaguchi, A. Y., Naylor, S. L., & Brewer, H. B. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.24.8340 · Cited by 108
Barter, P. J. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.9.2029 · Cited by 107
Holme, I., Aastveit, A. H., Jungner, I., & Walldius, G. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.01925.x · Cited by 106
The rationale for using apoA‐I as a clinical marker of cardiovascular risk
Barter, P. J., & Rye, K.-A. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01647.x · Cited by 104
Non-HDL cholesterol as a metric of good quality of care: opportunities and challenges.
Virani, S. S. (2011) · Europe PMC (PubMed Central) · Cited by 101
Gordon, D. A. (1997) · Current Opinion in Lipidology · doi:10.1097/00041433-199706000-00002 · Cited by 100
Wojczynski, M. K., Glasser, S. P., Oberman, A., Kabagambe, E. K., Hopkins, P. N., Tsai, M. Y., Straka, R. J., Ordovás, J. M., & Arnett, D. K. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-181 · Cited by 96
ApoB/apoA-I ratio: an independent predictor of insulin resistance in US non-diabetic subjects
Sierra-Johnson, J., Romero‐Corral, A., Somers, V. K., López-Jiménez, F. A., Walldius, G., Hamsten, A., Hellénius, M.-L., & Fisher, R. M. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm360 · Cited by 95
Cobbaert, C. M., Althaus, H., Brkovic, I. B., Ceglarek, U., Coassin, S., Delatour, V., Deprez, L., Dikaios, I., Dittrich, J., Hoofnagle, A. N., et al. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa239 · Cited by 95
Olsson, U., Camejo, G., Hurt-Camejo, E., Elfsber, K., Wiklund, O., & Bondjers, G. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.1.149 · Cited by 94
Cardiovascular Disease in Diabetes Mellitus
Szuszkiewicz-Garcia, M., & Davidson, J. A. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.09.001 · Cited by 93
Olofsson, S., Wiklund, O., & Borén, J. (2007) · PubMed Central · Cited by 93
A More Valid Measurement of Low-Density Lipoprotein Cholesterol in Diabetic Patients
Hirany, S. V., Dai, L., & Jialal, I. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00375-0 · Cited by 93
Apolipoprotein B: a predictor of inflammatory status in postmenopausal overweight and obese women
Faraj, M., Messier, L., Bastard, J., Tardif, A., Godbout, A., Prud’homme, D., & RABASA-LHORET, R. P. R. (2006) · Diabetologia · doi:10.1007/s00125-006-0259-7 · Cited by 92
Measurement of triglyceride-rich lipoproteins by nuclear magnetic resonance spectroscopy
Otvos, J. D. (1999) · Clinical Cardiology · doi:10.1002/clc.4960221405 · Cited by 88
Assembly of Very Low Density Lipoprotein: A Two-Step Process of Apolipoprotein B Core Lipidation
Rustaeus, S., Lindberg, K., Stillemark-Billton, P., Claesson, C., Asp, L., Larsson, T. P., Borén, J., & Olofsson, S. (1999) · Journal of Nutrition · doi:10.1093/jn/129.2.463s · Cited by 87
Ruscica, M., Zimetti, F., Adorni, M. P., Sirtori, C. R., Lupo, M. G., & Ferri, N. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104653 · Cited by 87
Ebara, T., Conde, K., Kako, Y., Liu, Y., Xu, Y., Ramakrishnan, R., Goldberg, I. J., & Shachter, N. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8283 · Cited by 86
Absolute quantification of apolipoproteins and associated proteins on human plasma lipoproteins
von Zychlinski, A., Williams, M. J. A., McCormick, S. P. A., & Kleffmann, T. (2014) · Journal of Proteomics · doi:10.1016/j.jprot.2014.04.030 · Cited by 83
Hermans, M. P., Sacks, F. M., Ahn, S. A., & Rousseau, M. F. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-20 · Cited by 83
Gisterå, A., Klement, M. L., Polyzos, K. A., Mailer, R. K., Duhlin, A., Karlsson, M. C. I., Ketelhuth, D. F. J., & Hansson, G. K. (2018) · Circulation · doi:10.1161/circulationaha.118.034076 · Cited by 82
Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apo B levels
Sniderman, A. D., Vu, H., & Cianflone, K. (1991) · Atherosclerosis · doi:10.1016/0021-9150(91)90050-d · Cited by 81
Cardiovascular Risk Assessment: A Systematic Review of Guidelines
Khanji, M. Y., Bicalho, V. V. D. S., van Waardhuizen, C. N., Ferket, B. S., Petersen, S. E., & Hunink, M. G. M. (2016) · Annals of Internal Medicine · doi:10.7326/m16-1110 · Cited by 81
Lomitapide: a review of its clinical use, efficacy, and tolerability
Alonso, R., Cuevas, A., & Mata, P. (2019) · Core Evidence · doi:10.2147/ce.s174169 · Cited by 81
Bodde, M. C., Hermans, M. P. J., Jukema, J. W., Schalij, M. J., Lijfering, W. M., Rosendaal, F. R., Romijn, F. P. H. T. M., Ruhaak, L. R., van der Laarse, A., & Cobbaert, C. M. (2018) · Clinical Research in Cardiology · doi:10.1007/s00392-018-1381-5 · Cited by 80
Silverio, A., Cavallo, P., Rosa, R. D., & Galasso, G. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00036 · Cited by 80
Aggregation and fusion of low-density lipoproteins in vivo and in vitro
Lu, M., & Gursky, O. (2013) · BioMolecular Concepts · doi:10.1515/bmc-2013-0016 · Cited by 79
Atherogenic lipoprotein phenotype and LDL size and subclasses in women with gestational diabetes
Rizzo, M., Berneis, K. K., Altınova, A. E., Törüner, F. B., Aktürk, M., Ayvaz, G., Rini, G. B., Spinas, G. A., & Arslan, M. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02613.x · Cited by 79
Langlois, M. R., & Sniderman, A. D. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01323-z · Cited by 79
Novel and traditional lipid profiles in Metabolic Syndrome reveal a high atherogenicity
Paredes, S., Fonseca, L., Ribeiro, L. V. P. T., Ramos, H., Oliveira, J. C., & Palma, I. (2019) · Scientific Reports · doi:10.1038/s41598-019-48120-5 · Cited by 78
Who needs to care about small, dense low-density lipoproteins?
Rizzo, M., & Berneis, K. K. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01596.x · Cited by 77
Molecular basis of familial hypercholesterolemia.
Russell, D. W., Esser, V., & Hobbs, H. H. (1989) · PubMed · Cited by 76
Rizzo, M., Pernice, V., Frasheri, A., & Berneis, K. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.03.034 · Cited by 75
Mechanism of lipoprotein retention by the extracellular matrix
Gustafsson, M., & Borén, J. (2004) · Current Opinion in Lipidology · doi:10.1097/00041433-200410000-00003 · Cited by 75
Rizzo, M., Spinas, G. A., Cesur, M., Özbalkan, Z., Rini, G. B., & Berneis, K. K. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.07.015 · Cited by 75
The crystal structure of human microsomal triglyceride transfer protein
Biterova, E. I., Isupov, M. N., Keegan, R. M., Lebedev, A. A., Sohail, A. A., Liaqat, I., Alanen, H. I., & Ruddock, L. W. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903029116 · Cited by 75
Sniderman, A. D., Islam, S., McQueen, M., Pencina, M. J., Furberg, C. D., Thanassoulis, G., & Yusuf, S. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003665 · Cited by 74
Risk of Premature Cardiovascular Disease vs the Number of Premature Cardiovascular Events
Sniderman, A. D., Thanassoulis, G., Williams, K., et al. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.0991 · Cited by 73
Shelness, G. S., Ingram, M. F., Huang, X. F., & DeLozier, J. A. (1999) · Journal of Nutrition · doi:10.1093/jn/129.2.456s · Cited by 72
A cross-species comparison of the apolipoprotein B domain that binds to the LDL receptor.
Law, A., & Scott, J. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42751-8 · Cited by 68
Chapman, M. J., Orsoni, A., Tan, R., Mellett, N. A., Nguyen, A., Robillard, P., Giral, P., Thérond, P., & Meikle, P. J. (2020) · Journal of Lipid Research · doi:10.1194/jlr.p119000543 · Cited by 65
Westerveld, H. T., van Lennep, J. E. R., van Lennep, H. W. O. R., Liem, A. H., de Boo, J. A. J., van der Schouw, Y. T., & Erkelens, D. W. (1998) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.18.7.1101 · Cited by 65
Association of Apolipoprotein B with Incident Type 2 Diabetes in an Aboriginal Canadian Population1
Ley, S. H., Harris, S. B., Connelly, P. W., Mamakeesick, M., Gittelsohn, J., Wolever, T. M. S., Hegele, R. A., Zinman, B., & Hanley, A. J. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2009.136994 · Cited by 65
Holewijn, S., Den Heijer, M., Swinkels, D. W., H Stalenhoef, A. F., & De Graaf, J. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02277.x · Cited by 64 · cited 1×
“ApoB was found to be a better predictor than non-HDL-C in identifying more patients with a compromised cardiovascular profile, according to a population-based sample [114].”
BackgroundGoldberg, I. J., Wagner, W. D., Pang, L., Paka, L., Curtiss, L. K., DeLozier, J. A., Shelness, G. S., Young, C. S. H., & Pillarisetti, S. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.52.35355 · Cited by 62
The spectrum of type III hyperlipoproteinemia
Sniderman, A. D., Graaf, J. D., Thanassoulis, G., Tremblay, A. J., Martin, S. S., & Couture, P. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.09.006 · Cited by 62
Inclisiran: a novel agent for lowering apolipoprotein B–containing lipoproteins
Warden, B. A., & Duell, P. B. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001053 · Cited by 62
The safety of over-the-counter niacin. A randomized placebo-controlled trial [ISRCTN18054903]
Mills, E. J., Prousky, J. E., Raskin, G., Gagnier, J. J., Rachlis, B., Montori, V. M., & Juurlink, D. N. (2003) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-3-4 · Cited by 61
Martin, S. S., Qasim, A. N., Mehta, N. N., Wolfe, M., Terembula, K., Schwartz, S., Iqbal, N., Schutta, M., Bagheri, R., & Reilly, M. P. (2009) · Diabetes · doi:10.2337/db08-1794 · Cited by 60
Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective
Elam, M. B., Lovato, L., & Ginsberg, H. N. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328341a5a8 · Cited by 59
Matthan, N. R., Jalbert, S. M., Barrett, P. H. R., Dolnikowski, G. G., Schaefer, E. J., & Lichtenstein, A. H. (2008) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.163931 · Cited by 57
Durrington, P. N., Bolton, C., & Hartog, M. (1978) · Clinica Chimica Acta · doi:10.1016/0009-8981(78)90038-4 · Cited by 56
Effects of Anacetrapib in Patients With Atherosclerotic Vascular Disease
Bowman, L., Hopewell, J. C., Chen, F., Wallendszus, K., & Stevens, W. (2017) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2017.11.029 · Cited by 56
Sandhu, P. K., Musaad, S. M. A., Remaley, A. T., Buehler, S. S., Strider, S., Derzon, J. H., Vesper, H. W., Ranne, A., Shaw, C. S., & Christenson, R. H. (2016) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2016.021006 · Cited by 55
Jiang, Z. G., Liu, Y., Hussain, M. M., Atkinson, D., & McKnight, C. J. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.09.006 · Cited by 55
Tian, M., Li, R., Shan, Z., Wang, D. W., Jiang, J., & Cui, G. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1144-y · Cited by 55
Apolipoprotein B Metabolism: Tracer Kinetics, Models, and Metabolic Studies
Burnett, J. R., & Barrett, P. H. R. (2002) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360208951113 · Cited by 54
Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice.
Birjmohun, R. S., Hutten, B. A., Kastelein, J. J. P., & Stroes, E. S. G. (2004) · PubMed · Cited by 53
Rosei, E. A., & Salvetti, M. (2016) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-016-0155-2 · Cited by 53
Vaccination against atherosclerosis
Kobiyama, K., Saigusa, R., & Ley, K. F. (2019) · Current Opinion in Immunology · doi:10.1016/j.coi.2019.02.008 · Cited by 50
Walldius, G., & Jungner, I. (2007) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2007.02.010 · Cited by 49
Mullick, A. E., Fu, W., Graham, M. J., Lee, R. G., Witchell, D. R., Bell, T. A., Whipple, C. P., & Crooke, R. M. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m011791 · Cited by 49
Conventional and Novel Lipid Measures and Risk of Peripheral Artery Disease
Kou, M., Ding, N., Ballew, S. H., Salameh, M., Martin, S. S., Selvin, E., HEISS, G. M., Ballantyne, C. M., Matsushita, K., & Hoogeveen, R. C. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315828 · Cited by 49
Systematic Review: Evaluating the Effect of Lipid-Lowering Therapy on Lipoprotein and Lipid Values
Rosenson, R. S., & Underberg, J. A. (2013) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-013-6477-6 · Cited by 47
Discordance between high non-HDL cholesterol and high LDL-cholesterol among US adults
Kilgore, M. L., Muntner, P., Woolley, J. M., Sharma, P., Bittner, V., & Rosenson, R. S. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.11.001 · Cited by 47
Keep recycling going: new approaches to reduce LDL-C
Klein-Szanto, A. J. P., & Bassi, D. E. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.04.003 · Cited by 46
How to assess and manage cardiovascular risk associated with lipid alterations beyond LDL
Averna, M. R., Stroes, E. S. G., Ogura, M., Postadzhiyan, A., Čerček, M., Calabrò, P., & Suppressa, P. (2017) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(17)30021-1 · Cited by 46
Discordance between lipoprotein particle number and cholesterol content: an update
Cantey, E. P., & Wilkins, J. T. (2018) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000389 · Cited by 46
Drexel, H., LARCHER, B., MADER, A., Vonbank, A., Heinzle, C. F., Moser, B., Zanolin-Purin, D., & Saely, C. H. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.05.010 · Cited by 46
Bays, H. E., McKenney, J. M., Dujovne, C. A., Schrott, H. G., Zema, M. J., Nyberg, J., & MacDougall, D. E. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00721-5 · Cited by 45
Li, N., Li, Q., Tian, X.-Q., Qian, H.-Y., & Yang, Y.-J. (2014) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-014-0077-0 · Cited by 45 · cited 5×
“The Friedewald equation, which is subject to inaccuracy in the presence of high triglycerides and other conditions like diabetes, estimates LDL-C as total cholesterol minus HDL-C and very-low-density cholesterol (VLDL-C), with VLDL-C estimated as triglycerides divided by a fixed factor of Metabolites 2021, 11, 690 6 o…”
BackgroundInfluentialHwang, Y., Ahn, H. Y., Park, H., & Park, C. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0587-x · Cited by 44
Sawle, A., Higgins, M. K., Olivant, M. P., & Higgins, J. A. (2002) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)30176-0 · Cited by 44
Mechanisms Targeting Apolipoprotein B100 to Proteasomal Degradation
Rutledge, A. C., Qiu, W., Zhang, R., Avramoglu, R. K., Nemat-Gorgani, N., & Adeli, K. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.181859 · Cited by 43
Molecular basis of familial hypercholesterolemia
Bruikman, C. S., Hovingh, G. K., & Kastelein, J. J. P. (2017) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000385 · Cited by 43
Ethnicity, lipids and cardiovascular disease
Gazzola, K., Reeskamp, L. F., & van den Born, B. H. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000412 · Cited by 43
Cited by
Peña-Jorquera, H., Cid-Jofré, V., Landaeta-Díaz, L., Petermann-Rocha, F., Martorell, M., Zbinden-Foncea, H., Ferrari, G., Jorquera-Aguilera, C., & Cristi-Montero, C. (2023) · Nutrients · doi:10.3390/nu15143244 · Cited by 103
RNA-binding proteins in vascular inflammation and atherosclerosis
Sachse, M., Tual-Chalot, S., Ciliberti, G., Amponsah-Offeh, M., Stamatelopoulos, K., Gatsiou, A., & Stellos, K. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.01.008 · Cited by 29
Metadata
- Authors
- Behbodikhah, J., Ahmed, S., Elyasi, A., Kasselman, L. J., De Leon, J., Glass, A. D., & Reiss, A. B.
- Venue
- Metabolites
- Publisher
- MDPI AG
- Published
- 2021-10-08
- Volume
- 11
- Issue
- 10
- Pages
- 690
- ISSN
- 2218-1989 (ISSN-L)
- OpenAlex
- W3207756665
- Cited by
- 270
- References
- 280
- FWCI
- 35.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.